The Trump administration's cancellation of NIH funding for clinical trials in cancer and other diseases could have disastrous ...

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...

A discovery published in Nature Immunology has shed light on why the immune system is less aggressive toward self-antigens, ...

Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National ...

A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or ...

LIKE mums all over the country, Katie Synnott should be busy tomorrow enjoying Mother’s Day with her four children, opening ...

WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...

Alan Tan, MD, discusses the 8-year follow-up data from the CheckMate 214 trial of patients with advanced renal cell carcinoma.